Item 1. Financial Statements
ITEM 1. FINANCIAL STATEMENTS
NEOVOLTA, INC.
Balance Sheets
(Unaudited)
December 31,
June 30,
2024
2024
Assets
Current assets:
Cash and cash equivalents
$ 328,746
$ 986,427
Accounts receivable, net
1,656,114
1,805,980
Inventory, net
2,033,258
1,787,308
Prepaid insurance and other current assets
–
76,815
Total current assets
4,018,118
4,656,530
Total assets
$ 4,018,118
$ 4,656,530
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$ 38,465
$ 5,316
Accrued liabilities
46,116
55,784
Short-term notes payable
249,711
–
Total current liabilities
334,292
61,100
Payable to line of credit lender
383,538
–
Total liabilities
717,830
61,100
Commitments and contingencies (Note 4)
–
–
Stockholders’ equity:
Common stock, $ 0.001 par value, 100,000,000 shares authorized, 33,417,123 and 33,236,091 shares,
respectively, issued and outstanding
33,417
33,236
Additional paid-in capital
25,945,040
25,304,732
Accumulated deficit
( 22,678,169 )
( 20,742,538 )
Total stockholders’ equity
3,300,288
4,595,430
Total liabilities and stockholders’ equity
$ 4,018,118
$ 4,656,530
See accompanying notes to unaudited financial statements.
4
NEOVOLTA, INC.
Statements of Operations
(Unaudited)
Three Months Ended
December 31,
2024
2023
Revenues from contracts with customers
$ 1,071,581
$ 1,017,828
Cost of goods sold
747,670
811,955
Gross profit
323,911
205,873
Operating expenses:
General and administrative
1,228,517
774,698
Research and development
42,324
–
Total operating expenses
1,270,841
774,698
Loss from operations
( 946,930 )
( 568,825 )
Other income (expense):
Interest expense
( 24,546 )
–
Interest income
339
12,781
Total other income (expense)
( 24,207 )
12,781
Net loss
$ ( 971,137 )
$ ( 556,044 )
Weighted average shares outstanding - basic and diluted
33,301,150
33,226,411
Net loss per share - basic and diluted
$ ( 0.03 )
$ ( 0.02 )
See accompanying notes to unaudited financial statements.
5
NEOVOLTA, INC.
Statements of Operations
(Unaudited)
Six Months Ended
December 31,
2024
2023
Revenues from contracts with customers
$ 1,661,817
$ 1,781,958
Cost of goods sold
1,245,059
1,454,913
Gross profit
416,758
327,045
Operating expenses:
General and administrative
2,278,636
1,329,858
Research and development
50,941
–
Total operating expenses
2,329,577
1,329,858
Loss from operations
( 1,912,819 )
( 1,002,813 )
Other income (expense):
Interest expense
( 24,546 )
–
Interest income
1,734
18,054
Total other income (expense)
( 22,812 )
18,054
Net loss
$ ( 1,935,631 )
$ ( 984,759 )
Weighted average shares outstanding - basic and diluted
33,300,247
33,190,769
Net loss per share - basic and diluted
$ ( 0.06 )
$ ( 0.03 )
See accompanying notes to unaudited financial statements.
6
NEOVOLTA, INC.
Statements of Stockholders’ Equity
Three and Six Months Ended December 31, 2024
and 2023
(Unaudited)
Additional
Total
Common Stock
Paid-in
Accumulated
Stockholders’
Shares
Amount
Capital
Deficit
Equity
Balance at June 30, 2024
33,236,091
$ 33,236
$ 25,304,732
$ ( 20,742,538 )
$ 4,595,430
Stock compensation expense
9,776
10
265,389
–
265,399
Net loss
–
–
–
( 964,494 )
( 964,494 )
Balance at September 30, 2024
33,245,867
33,246
25,570,121
( 21,707,032 )
3,896,335
Stock compensation expense
115,844
116
214,574
–
214,690
Exercise of common stock warrants
55,412
55
160,345
–
160,400
Net loss
–
–
–
( 971,137 )
( 971,137 )
Balance at December 31, 2024
33,417,123
$ 33,417
$ 25,945,040
$ ( 22,678,169 )
$ 3,300,288
Additional
Total
Common Stock
Paid-in
Accumulated
Stockholders’
Shares
Amount
Capital
Deficit
Equity
Balance at June 30, 2023
33,155,127
$ 33,155
$ 24,872,446
$ ( 18,439,228 )
$ 6,466,373
Stock compensation expense
–
–
84,717
–
84,717
Net loss
–
–
–
( 428,715 )
( 428,715 )
Balance at September 30, 2023
33,155,127
33,155
24,957,163
( 18,867,943 )
6,122,375
Stock compensation expense
80,964
81
97,060
–
97,141
Net loss
–
–
–
( 556,044 )
( 556,044 )
Balance at December 31, 2023
33,236,091
$ 33,236
$ 25,054,223
$ ( 19,423,987 )
$ 5,663,472
See accompanying notes to unaudited financial statements.
7
NEOVOLTA, INC.
Statements of Cash Flows
(Unaudited)
Six Months Ended
December 31,
2024
2023
Cash flows from operating activities:
Net loss
$ ( 1,935,631 )
$ ( 984,759 )
Adjustments to reconcile net loss to net cash used in operations:
Stock compensation expense
480,089
181,858
Provision for expected credit losses/bad debt expense
218,441
330,000
Changes in current assets and liabilities
Accounts receivable
( 68,575 )
( 689,426 )
Inventory
( 245,950 )
598,738
Prepaid insurance and other current assets
76,815
87,814
Accounts payable
33,149
–
Accrued expenses
( 9,668 )
( 27,722 )
Net cash flows used in operating activities
( 1,451,330 )
( 503,497 )
Cash flows from financing activities:
Borrowings under line of credit
500,000
–
Repayments of line of credit
( 116,462 )
–
Borrowings under short-term notes payable
389,732
–
Repayments of short-term notes payable
( 140,021 )
–
Proceeds from exercise of common stock warrants
160,400
–
Net cash flows provided by financing activities
793,649
–
Net decrease in cash and cash equivalents
( 657,681 )
( 503,497 )
Cash and cash equivalents at beginning of period
986,427
2,002,789
Cash and cash equivalents at end of period
$ 328,746
$ 1,499,292
Supplemental disclosures of cash flow information
Cash paid for interest
$ 9,306
$ –
Cash paid for income taxes
–
–
See accompanying notes to unaudited financial statements.
8
NEOVOLTA, INC.
Notes to Financial Statements
(Unaudited)
(1) Business
and Summary of Significant Accounting Policies
Description of Business
– NeoVolta Inc. (“we”, “our” or the “Company”) is a Nevada corporation, which was formed on March
5, 2018. The Company is a designer, seller and manufacturer of Energy Storage Systems (ESS) which can store and use energy via batteries
and an inverter at residential and commercial sites. The Company sells its proprietary ESS units through wholesale customers, primarily
in California, and in an expanding number of other states. In August 2022, the Company completed an underwritten public offering of its
equity securities resulting in its common stock and warrants becoming listed on a national exchange (see Note 3).
Interim Financial Information
– The Company has prepared the accompanying financial statements, without audit, in accordance with accounting principles generally
accepted in the Unites States of America for interim financial information and pursuant to the rules and regulations of the Securities
and Exchange Commission (“SEC”). In the opinion of management, these financial statements contain all adjustments, consisting
only of normal recurring adjustments, necessary to fairly state the Company’s financial position as of December 31, 2024, the results
of its operations for the three and six month periods ended December 31, 2024 and 2023, the changes in its stockholders’ equity
for the three and six month periods ended December 31, 2024 and 2023, and cash flows for the six month periods ended December 31, 2024
and 2023. The balance sheet as of June 30, 2024 has been derived from the Company’s June 30, 2024 financial statements that were
audited by an independent registered public accounting firm but does not include all of the information and footnotes required for complete
annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected
for the full year. These financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended June
30, 2024, as filed with the SEC on September 27, 2024.
Cash and Cash Equivalents
– The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to
be cash equivalents. Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured
limit of $250,000, per bank. At December 31, 2024, the Company maintained all of its accounts at one bank and the combined balances of
all accounts at this bank was in excess of the FDIC insurance limit by $78,746.
Inventory – Inventory
consists of batteries and inverters purchased from Asian suppliers and delivered to a location near the Company’s offices, for assembly
into ESS units. Inventory is stated at the lower of cost or net realizable value, cost being determined using the first-in, first out
(FIFO) method. The Company periodically reviews the value of items in inventory and records an allowance to reduce the carrying value
of inventory to the lower of cost or net realizable value based on its assessment of market conditions, inventory turnover and current
stock levels. Inventory write-downs are charged to cost of goods sold. The following table presents the components of inventory (net of
prior year reserve for obsolescence on assembly parts of $90,000) as of December 31, 2024 and June 30, 2024:
Schedule of inventory
December 31,
2024
June 30,
2024
Raw materials, consisting of assembly parts, batteries and inverters
$ 1,615,565
$ 1,076,479
Work in progress
–
89,386
Finished goods
417,693
621,443
Total
$ 2,033,258
$ 1,787,308
9
Revenue Recognition
– The Company recognizes revenue in accordance with Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts
with Customers (Topic 606). Revenues are recognized when control of the promised goods is transferred to the customer in an amount that
reflects the consideration the Company expects to be entitled to in exchange for transferring those goods or services. Revenue is recognized
based on the following five step model:
· Identification of the contract with a customer
· Identification of the performance obligations in the contract
· Determination of the transaction price
· Allocation of the transaction price to the performance obligations in the contract
· Recognition of revenue when, or as, the Company satisfies a performance obligation
The Company generates revenues
from contracts with customers, consisting of a relatively small number of wholesale dealers and installers, primarily in California. Two
such dealers represented approximately 37 % and 34 % of the Company’s revenues in the three months ended December 31, 2024, however,
no other dealers accounted for more than 10% of the revenues in such period. Two such dealers represented approximately 35 % and 33 % of
the Company’s revenues in the six months ended December 31, 2024. Four dealers represented approximately 31 %, 25 %, 23 % and 21 % of
the Company’s accounts receivable as of December 31, 2024. Two dealers represented approximately 51 % and 15 % of the Company’s
revenues in the three months ended December 31, 2023. Three dealers represented approximately 29 %, 20 % and 10 % of the Company’s
revenues in the six months ended December 31, 2023. Since all of the Company’s revenue is currently generated from the sales of
similar products, no further disaggregation of revenue information for the three and six months ended December 31, 2024 and 2023 is provided.
Allowance for Expected
Credit Losses – The Company recognizes an allowance for expected credit losses whenever a loss is expected to be incurred
in the realization of a customer’s account. As of December 31, 2024 and June 30, 2024, our allowance for expected credit losses
was $ 640,000 and $ 1,030,000 , respectively.
Stock Compensation Expense
– Employee and non-employee share-based payment compensation is measured at the grant date, based on the fair value of the award,
and is recognized as an expense over the requisite service period.
Loss Per Common Share
– Basic loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of
common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares
outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the
weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.
As of December 31, 2024, the Company had total outstanding common stock equivalents of 2,547,512 shares as follows: (i) 1,416,362 shares
related to restricted stock units granted to an officer and two other employees since April 2024; (ii) 1,081,150 shares related to warrants
issued to investors in the public offering completed in August 2022; and (iii) 50,000 shares related to restricted stock units granted
to an officer in March 2022 (see Note 3).
Research and Development
Costs – Research and development costs are expensed as incurred.
Use of Estimates –
Management has made a number of estimates and assumptions in preparing these financial statements in conformity with accounting principles
generally accepted in the United States of America. Actual results could differ from those estimates.
10
Recent Accounting Pronouncements
– From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, (“FASB”),
or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently
issued and prospective standards that are not yet effective will not have a material impact on the Company’s financial position
or results of operations upon adoption. The Company has considered all other recently issued accounting pronouncements and does not believe
the adoption of such pronouncements will have a material impact on its financial statements.
Liquidity – These
financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge
its liabilities in the normal course of business. The continuation of the Company as a going concern has been dependent upon the ability
of the Company to obtain necessary debt and equity financing to continue operations and the attainment of profitable operations.
As disclosed in Note 2, we
entered into an agreement with a financing entity in September 2024 whereby we have obtained a line of credit for borrowings of up to
$ 5,000,000 , in order to meet any near-term borrowing needs. As a result, we believe that we will have sufficient financial resources available
to us in order to operate our business for at least the next 12 months from the date these financial statements are issued.
(2) Debt
Financing Transactions
On September 3, 2024, we entered
into an agreement with a newly formed financing entity whereby we obtained a line of credit for borrowings of up to $ 5,000,000 . Under
this agreement, we are obligated to make periodic payments to the lender of accrued interest, at the rate of 16 % per annum, on any outstanding
borrowings that we make, with the principal and any unpaid accrued interest being due at maturity on September 3, 2026 . In order to secure
such borrowings, we have granted a security interest in all of our assets to the lender. As a condition of receiving this line of credit
from the lender, we have agreed not to issue any securities pursuant to the Company’s Form S-3 (file number 333-280400), without
the lender’s consent, so long as any borrowings remain outstanding. As of December 31, 2024, we had made net borrowings under this
credit agreement in the amount of $ 383,538 , leaving an available balance of $ 4,616,462 . Accrued interest as of December 31, 2024 was $ 13,595 ,
of which none had been paid.
On October 4, 2024, we made
an initial borrowing of $ 250,000 under this line of credit largely in order to fund a short-term loan in the same amount to a new customer
which has a government-backed contract to install a large number of our units in Puerto Rico over a two year period. The purpose of the
loan was to provide working capital to the customer in conjunction with the startup of the contract in Puerto Rico. The loan was structured
to be non-interest bearing, if repaid prior to December 31, 2024. The loan was fully repaid in December 2024.
In the month of November 2024,
we initiated short-term borrowings from a commercial lender under a loan agreement allowing for borrowings, secured by certain property
interests, of up to $2,000,000. As of December 31, 2024, we had made borrowings from this lender to finance four shipments to the new
customer in Puerto Rico in the total amount of $ 371,997 . The lender charges a placement fee of 1% on each borrowing and assesses interest
at the rate of 2.5% per month on the outstanding borrowings. Borrowings are to be repaid upon the earlier of: (i) 120 days from the borrowing
date; or (ii) receipt of payment from the customer in Puerto Rico. In the event of default, interest is assessed at the default rate of
1% per 7 days. Through December 31, 2024, we had repaid one such borrowing, including accrued interest and fees, in the total amount of
$ 140,021 , leaving an outstanding balance as of that date, including accrued interest and fees of $ 17,735 , in the total amount of $ 249,711 .
11
(3) Equity
Common Stock –
In August 2022, the Company completed an underwritten public offering of its equity securities in the form of Units with each Unit consisting
of one share of common stock and one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase
one share of common stock at an exercise price of $4.00 per share. The shares of common stock and the Warrants comprising the Units were
immediately separated at closing of the offering and each is now independently listed on the NASDAQ Capital Market. Each Warrant became
exercisable on the date of issuance and will expire five years from the date of issuance.
In the underwritten public
offering, a total of 1,121,250 Units, including exercise of the underwriter’s overallotment option, were sold at an offering price
to the public of $4.00 per Unit. The gross proceeds of the offering were $ 4,485,000 and the net proceeds, after deduction of underwriting
discounts and other offering costs were approximately $ 3,780,000 . The Company also granted the underwriter non-tradeable warrants to purchase
a total of 58,500 shares of common stock at an exercise price of $ 4.40 per share for a period of five years.
In conjunction with the public
offering, all holders of the Company’s 2018 convertible notes in the total amount of $ 59,251 , including accrued interest, converted
their debt into a total of 9,404,867 shares of common stock at the stated conversion rate, and all holders of the Company’s 2021
convertible notes in the total amount of $ 1,120,035 , including accrued interest, automatically converted their debt into a total of 267,000
shares of common stock at the stated conversion rate.
Warrants – The
Warrants for a total of 1,179,750 shares of common stock issued to investors and the underwriters are exercisable at any time after their
original issuance and at any time up to the date that is five years after their original issuance, or August 1, 2027 . The Warrants may
be exercised upon payment of the exercise price in cash on or prior to the expiration date. Under the terms of the Warrant Agreement,
we must use our best efforts to maintain the effectiveness of the registration statement and current prospectus relating to common stock
issuable upon exercise of the Warrants until the expiration of the Warrants. If we fail to maintain the effectiveness of the registration
statement and current prospectus relating to the common stock issuable upon exercise of the Warrants, the holders of the Warrants shall
have the right to exercise the Warrants solely via a cashless exercise feature provided for in the Warrants, until such time as there
is an effective registration statement and current prospectus.
The following table presents
activity with respect to the Company’s warrants for the six months ended December 31, 2024:
Schedule of warrant activity
Number
Wtd. Avg.
Wtd. Avg.
Aggregate
of
Exercise
Remaining
Intrinsic
Shares
Price
Term (Yrs.)
Value
Outstanding at June 30, 2024
1,179,750
$ 4.02
Warrants issued
–
–
Warrants exercised/forfeited
( 98,600 )
( 4.24 )
Outstanding at December 31, 2024
1,081,150
$ 4.00
2.6
$ 1,308,192
Exercisable at December 31, 2024
1,081,150
$ 4.00
2.6
$ 1,308,192
These warrants were issued
in conjunction with an underwritten public equity offering, therefore, there was no employee or non-employee compensation expense recognized.
In November 2024, the underwriter elected to exercise all 58,500 Warrants at an exercise price of $4.40 per share, via a cashless exercise,
as permitted under the warrant agreement, resulting in the issuance of 15,312 shares of our common stock. Additionally, the holders of
publicly issued Warrants to purchase an aggregate of 40,100 shares of our common stock elected to exercise their Warrants by a cash payment
of a total of $ 160,400 resulting in the issuance of the underlying shares of our common stock in December 2024.
12
Stock Compensation Expense
– In April 2024, we entered into an employment agreement with a new Chief Executive Officer (“CEO”), providing
for an initial term extending through June 30, 2027, which will be automatically renewed for additional one-year terms unless either
party chooses not to renew it. Pursuant to the agreement, our new CEO received an initial equity grant equal to 1,280,000 restricted
stock units (“RSU’s”), with a grant date value of $ 2,854,000 , which will vest over a four-year period, subject to his
continued employment with the Company, and will be entitled to earn additional RSU’s on each anniversary in the form of three annual
performance-based equity grants, beginning in the year ending June 30, 2025, with a target value of up to $660,000 each. However, no
such additional grants have been made as of December 31, 2024.
In February 2022, we entered
into a new employment agreement with our then CEO, effective April 1, 2022. As noted above, we engaged a new CEO effective April 29, 2024,
replacing our former CEO who remains as Chairman of the Board and chief technology officer. Pursuant to the agreement, we issued our former
CEO an RSU award for up to 150,000 shares of our common stock upon achieving the following milestones (which achievements shall be determined
by the Board): (i) Milestone 1 - Successfully complete an uplisting of our common stock in 2022 and continue his employment with our company
until January 1, 2023: 50,000 shares; and (ii) Milestone 2 - Produce 2,000 ESSs in 2022 and continue his employment with our company until
January 1, 2023: 100,000 shares. As of December 31, 2023, Milestone 1 had been achieved, however, Milestone 2 had not been achieved and
was no longer achievable. The underlying 50,000 shares of common stock earned under Milestone 1 were issued to our former CEO as of January
1, 2023.
In February 2022, we entered
into a new employment agreement with our Chief Financial Officer (“CFO”), effective March 1, 2022. Pursuant to the agreement,
we issued our CFO an RSU award for up to 300,000 shares of our common stock upon achieving the following milestones (which achievements
shall be determined by the Board): (i) Milestone 1 - Successfully complete an uplisting of our common stock in 2022 and continue his employment
with our company until January 1, 2023: 250,000 shares; and (ii) Milestone 2 - successfully complete and file the Company’s Form
10-K for the year ended June 30, 2023 no later than September 29, 2023 and continue his employment with our company until January 1, 2024:
50,000 shares. Milestone 1 was achieved as of January 1, 2023, and the underlying 250,000 shares of common stock earned under Milestone
1 were issued to our CFO as of that date. Milestone 2 was achieved as of January 1, 2024, and the underlying 50,000 shares of common stock
earned under Milestone 2 are expected to be issued to our CFO at a later date (see Note 5).
Based upon our assessment
of the probability of our three executive officers noted above, plus the non-executive recipient of two other RSU award issued in June
2024 and October 2024, ultimately achieving any applicable milestones specified under the RSU awards indicated above, we have calculated
the grant date value of such awards and are amortizing it as stock compensation expense over the underlying performance periods. We have
recognized stock compensation expense applicable to such RSU awards in the six months ended December 31, 2024 and 2023 in the amounts
of $ 392,339 and $ 81,683 , respectively
In conjunction with our public
offering in August 2022, we appointed two new independent directors and adopted a new compensation plan for all independent directors
based on an annual compensation amount of $65,000 with not less than 70% of such amount paid in shares of our common stock, calculated
based on the share price at the end of such prior fiscal quarter, and up to 30% paid in cash, with such final amounts to be determined
by each director. As of December 31, 2024, we booked an accrual of $ 97,500 of compensation expense (of which $87,750 will be settled through
the issuance of shares) for our three independent directors under this plan.
In the six months ended December
31, 2024, we recognized total non-cash stock compensation expense of $ 480,089 as follows: (i) $ 392,339 for the amortized value of the
RSUs granted to our chief executive officer, as previously described, and two other non-executive recipients of RSU awards granted since
June 2024; and (ii) $ 87,750 for the amortized value of the portion of the new compensation plan for our independent directors that is
attributable to stock. There were a total of 125,620 shares of our common stock that were issued to various grantees in the six months
ended December 31, 2024, which were previously expensed in the year ended June 30, 2024.
13
In the six months ended December
31, 2023, we recognized total non-cash stock compensation expense of $ 181,858 as follows: (i) $ 81,683 for the amortized value of the RSUs
granted to our two executive officers, as previously described; (ii) $ 87,750 for the amortized value of the portion of the new compensation
plan for our independent directors that is attributable to stock; and (iii) $ 12,425 for the fair value of incentive shares earned by a
wholesale dealer as of December 31, 2023 (see Note 4). There was a total of 80,964 shares of common stock that were issued to independent
directors and advisors in the six months ended December 31, 2023, which were previously expensed in the year ended June 30, 2023.
Other Matters –
In February 2019, the Company’s Board of Directors approved the establishment of a new 2019 Stock Plan (“Plan”) with
an authorization for the issuance of up to 2,500,000 shares of common stock. In December 2024, the Plan was amended to increase the number
of shares of common stock authorized for issuance by 5,000,000 shares. The Plan is designed to provide for future discretionary grants
of stock options, stock awards and stock unit awards to key employees, consultants, advisors, and non-employee directors. As of December
31, 2024, we have made total awards of 2,060,804 shares under the Plan as follows: (i) 1,866,362 shares for the RSUs granted to our three
executive officers and two non-executive recipients, as noted above; (ii) 153,808 shares for the initial services of our three independent
directors in the years ended June 30, 2024 and 2023, pursuant to the new compensation plan adopted in August 2022 for independent directors;
and (iii) 40,634 shares granted to several wholesale dealers under an incentive sales program.
(4)
Commitments and Contingencies
Effective January 1, 2021,
we secured new corporate and manufacturing office space under a sublease agreement with a company that served as our contract manufacturer
at that time. Under the terms of the sublease agreement, we were required to make rental payments of $10,350 per month during the initial
one-year term of the agreement. Further, under the terms of the sublease agreement, we were granted the right to renew the sublease for
additional terms of 12 months each upon mutual agreement of both parties, provided thirty days’ notice is given for each subsequent
term, at a modest increase in the monthly rent, through December 31, 2024, with no obligation to renew it. At inception of the sublease,
management determined that exercise of the renewal option was not reasonably certain and, notwithstanding that the Company elected to
renew the agreement for additional one year periods as of January 1, 2022, 2023 and 2024. Accordingly, we have accounted for it as a short-term
lease under ASC 842, Leases . Effective December 31, 2024, the parties mutually agreed to a short-term extension of the sublease
agreement, on essentially the same terms, through February 28, 2025. Prior to expiration of the extended sublease, the Company relocated
its corporate and manufacturing office space to another facility in the same vicinity under a one year sublease agreement with the sublandlord,
at a base rental of $15,532 per month.
As indicated in Note 1, we
sell our proprietary ESS units through wholesale dealers, primarily in California. In that regard, we have entered into agreements with
several wholesale dealers operating in California and other states under which we have incentivized the dealers to achieve quarterly sales
above targeted levels by agreeing to grant them shares of our common stock for exceeding such quarterly sales targets, determined as of
the calendar year end, subject to defined maximums, as determined annually on a calendar year basis.
We are dependent on our two
main component vendors for our suppliers of batteries, inverters and other raw materials and the inability of these single-source suppliers
to deliver necessary components of our products according to our schedule and at prices, quality levels and volumes acceptable to us,
or our inability to efficiently manage these components, could have a material adverse effect on our financial condition and operating
results.
From time to time in the ordinary
course of our business, the Company may be involved in legal proceedings, the outcomes of which may not be determinable. The Company is
not involved in any legal proceedings at this time. The results of litigation are inherently unpredictable. Any claims against us, whether
meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in
diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal
matters for which losses are not probable and estimable.
14
(5) Subsequent Events
On February 4, 2025, the Company
entered into an agreement with an accredited investor group under which the Company issued a total of 500,000 shares of its common stock
to the investor group at an offering price of $2.00 per share resulting in gross proceeds to the Company in the amount of $1,000,000.
The Company expects to use the proceeds of this private offering to meet working capital needs and for other general corporate purposes.
On February 4, 2025, Brent
Willson retired as the Chairman of the Board of Directors and Ardes Johnson, the Company’s chief executive officer, was elected
as a director and as the new Chairman of the Board of Directors.
Effective February 4, 2025,
the Company’s Board of Directors and Compensation Committee approved an amended and restated employment agreement with the Company’s
chief financial officer (“CFO”). The initial term of the employment agreement ends on December 31, 2027 and will be automatically
renewable for additional one-year terms unless either party chooses not to renew the agreement. Pursuant to the agreement, we issued our
CFO an award of 240,000 RSUs vesting in four annual installments.
In February 2025, the Company
entered into a referral agreement with a marketing company to market the Company’s products to qualified solar and energy storage
system installers. The term of the referral agreement ends on December 31, 2026. The agreement provides for the issuance of shares of
the Company’s common stock in exchange for reaching specified target levels of product sales, up to a maximum total of 2,000,000
shares for reaching a total of 2,500 units sold and paid for.
15
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.